semaglutide cardiac protection Cardiovascular outcomes of and tirzepatide for patients with type 2 diabetes in clinical practice Semaglutide ameliorates pressure overload-induced cardiac

While research on semaglutide and sexual function is limited, studies show weight loss and improved metabolic health can lead to better sexual function, particularly in people with obesity

Always store your drops in the original amber or opaque container provided by the pharmacy

5 This was an exciting study that was published recently in the New England Journal of Medicine and it was the first time we had compared tirzepatide with a GLP-1 agonist (semaglutide) in people with T2D. Figure 1 shows the design of the SURPASS-2 study 1,4 *Patients with T2D who had inadequate glycemic control on stable doses of metformin alone to receive once-weekly SC tirzepatide 5 mg, 10 mg, 15 mg, or once-weekly SC semaglutide 1 mg (1:1:1:1 ratio), all in combination with metformin 1500 mg/day

Many patients achieve excellent metabolic and weight outcomes without significant nausea, while others with mild nausea achieve comparable results

Tirzepatide and semaglutide shared similar rates for nausea, diarrhea, abdominal pain, and dyspepsia, but semaglutide had higher rates of vomiting, constipation, and GERD